Literature DB >> 46215

Interaction of complex polysaccharides with the complement system: effect of calcium depletion on terminal component consumption.

R Snyderman, M C Pike.   

Abstract

Complex polysaccharides and lipopolysaccharides can activate the terminal components of complement by either the classical (antibody, C1, C4, and C2) or alternative complement pathways, but the relative importance of either pathway for terminal component consumption in normal serum is poorly understood. Since classical complement pathway function requires both calcium and magnesium ions, whereas the alternative pathway requires only magnesium ions, selective chelation of calcium ions in serum can be used to block the classical complement pathway while leaving the alternative pathway intact. In these studies, ethyleneglycol-bis-(beta-aminoethyl ether)N, N-tetraacetic acid, a potent chelator or calcium, was used to block the classical complement pathway in normal guinea pig serum. Consumption of the terminal complement components by endotoxin, inulin, and zymosan in such serum was strikingly depressed when compared to serum containing an intact classical complement pathway. These studies demonstrate that in normal serum, both the classical and alternative complement pathways participate in the consumption of the terminal complement components by complex polysaccharides and lipopolysaccharides.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 46215      PMCID: PMC415056          DOI: 10.1128/iai.11.2.273-279.1975

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  25 in total

1.  The complement system.

Authors:  M M Mayer
Journal:  Sci Am       Date:  1973-11       Impact factor: 2.142

2.  The reaction of zymosan with the properdin system in normal and C4-deficienct guinea pig serum. Demonstration of C3- and C5-cleaving multi-unit enzymes, both containing factor B, and acceleration of their formation by the classical complement pathway.

Authors:  V Brade; G D Lee; A Nicholson; H S Shin; M M Mayer
Journal:  J Immunol       Date:  1973-11       Impact factor: 5.422

Review 3.  Highlights of complement research during the past twenty-five years.

Authors:  M M Mayer
Journal:  Immunochemistry       Date:  1970-05

Review 4.  Significance of complement to the mechanism of action of endotoxin.

Authors:  S E Mergenhagen; R Snyderman; H Gewurz; H S Shin
Journal:  Curr Top Microbiol Immunol       Date:  1969       Impact factor: 4.291

5.  Macrophage proteinase and inflammation: the production of chemotactic activity from the fifth complement by macrophage proteinase.

Authors:  R Snyderman; H Shin; A M Dannenberg
Journal:  J Immunol       Date:  1972-10       Impact factor: 5.422

6.  Production of chemotactic activity by guinea pig immunoglobulins following activation of the C3 complement shunt pathway.

Authors:  A L Sandberg; R Snyderman; M M Frank; A G Osler
Journal:  J Immunol       Date:  1972-05       Impact factor: 5.422

7.  Effect of C4 depletion on the utilization of the terminal components of guinea-pig complement by endotoxin.

Authors:  R Snyderman; H Gewurz; S E Mergenhagen; J Jensen
Journal:  Nat New Biol       Date:  1971-06-02

8.  Complement activity and inflammatory neutrophil exudation in man. Studies in patients with glomerulonephritis, essential hypocomplementemia and agammaglobulinemia.

Authors:  H Gewurz; A R Page; R J Pickering; R A Good
Journal:  Int Arch Allergy Appl Immunol       Date:  1967

9.  In vitro studies of complement function in sera of C4-deficient guinea pigs.

Authors:  M M Frank; J May; T Gaither; L Ellman
Journal:  J Exp Med       Date:  1971-07-01       Impact factor: 14.307

10.  A specific inactivator of mammalian C'4 isolated from nurse shark (Ginglymostoma cirratum) serum.

Authors:  J A Jensen
Journal:  J Exp Med       Date:  1969-08-01       Impact factor: 14.307

View more
  16 in total

1.  Serum resistance in an invasive, nontypeable Haemophilus influenzae strain.

Authors:  B J Williams; G Morlin; N Valentine; A L Smith
Journal:  Infect Immun       Date:  2001-02       Impact factor: 3.441

2.  Activation of the alternative pathway of complement by Entamoeba histolytica.

Authors:  L Ortiz-Ortiz; R Capin; N R Capin; B Sepúlveda; G Zamacona
Journal:  Clin Exp Immunol       Date:  1978-10       Impact factor: 4.330

Review 3.  The effects of bacterial endotoxins on host mediation systems. A review.

Authors:  D C Morrison; R J Ulevitch
Journal:  Am J Pathol       Date:  1978-11       Impact factor: 4.307

4.  Fate of 51Cr-labeled lipopolysaccharide in tissue culture cells and livers of normal mice.

Authors:  J C Zlydaszyk; R J Moon
Journal:  Infect Immun       Date:  1976-07       Impact factor: 3.441

5.  Inhibition of lipopolysaccharide-initiated activation of serum complement by polymyxin B.

Authors:  D C Morrison; D M Jacobs
Journal:  Infect Immun       Date:  1976-01       Impact factor: 3.441

6.  Evaluation of anticoagulants for serologic assays of cholera vaccination.

Authors:  Jae Seung Yang; Seok-Seong Kang; Cheol-Heui Yun; Seung Hyun Han
Journal:  Clin Vaccine Immunol       Date:  2014-04-09

7.  Human complement activation by lipopolysaccharides from bacteroides oralis, fusobacterium nucleatum, and veillonella parvula.

Authors:  H Nygren; G Dahlén; L A Nilsson
Journal:  Infect Immun       Date:  1979-11       Impact factor: 3.441

8.  Selective activation of classical and alternative pathways of human complement by "promptly serum-sensitive" and "delayed serum-sensitive" strains of Serratia marcescens.

Authors:  W H Traub; I Kleber
Journal:  Infect Immun       Date:  1976-05       Impact factor: 3.441

9.  Susceptibility of pathogenic and nonpathogenic Naegleria spp. to complement-mediated lysis.

Authors:  L Y Whiteman; F Marciano-Cabral
Journal:  Infect Immun       Date:  1987-10       Impact factor: 3.441

10.  Comparison of ethyleneglycoltetraacetic acid and its magnesium salt as reagents for studying alternative complement pathway function.

Authors:  D P Fine
Journal:  Infect Immun       Date:  1977-04       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.